Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,634
Total Claims
$1.3M
Drug Cost
609
Beneficiaries
$2,147
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+205%
Opioid rate vs peers
7.9% vs 2.6% avg
+101%
Cost per patient vs peers
$2,147 vs $1,068 avg
+83%
Brand preference vs peers
16.5% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid rate is 205% above Family Practice peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
7.9%
Opioid Rate
836
Opioid Claims
$23K
Opioid Cost
8.4%
Long-Acting Rate
Brand vs Generic
Brand: 1,719 claims · $1.1M
Generic: 8,723 claims · $208K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 142 | $166K |
| Apixaban | 176 | $123K |
| Dulaglutide | 75 | $99K |
| Semaglutide | 38 | $52K |
| Linagliptin | 48 | $44K |
| Insulin Degludec | 41 | $42K |
| Ipratropium/Albuterol Sulfate | 47 | $38K |
| Empagliflozin | 34 | $38K |
| Insulin Glargine,hum.Rec.Anlog | 53 | $30K |
| Mirabegron | 33 | $29K |
| Sitagliptin Phosphate | 27 | $27K |
| Insulin Aspart | 29 | $25K |
| Insulin Glargine,hum.Rec.Anlog | 48 | $24K |
| Insulin Detemir | 28 | $23K |
| Dapagliflozin Propanediol | 23 | $20K |
Prescribing Profile
Patient Profile
74
Avg Age
60%
Female
1.28
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About